Ann: Trading Halt, page-32

The $130bn (by 2024) US cannabis market is ripe for the taking, and I fully support the strategic direction CPH is taking, along with all of the other exciting supply agreements, Halucenex Life Sciences acquisition, new product R&D.

The global regulatory reclassification and attitude shift toward cannabis and psilocybin toward legalisation only really began in earnest in November last year, which I think is where CPH's real journey began. The aggressive business posturing has attracted high costs (which I was initially concerned about), but I've come to appreciate that although we have a global footprint, we are one of many players and need to be on the front foot with supply deals, partnerships, acquisitions, developing+registering products and getting them on to shelves and online stores ASAP. If CPH didn't adopt this approach, we'd run the risk of retaining status as a small time ASX cannabis player like some of the others.

This particular CR is to support the high costs associated with the US OTC registration and listing.

For CPH investors, this CR is to support this next big move in the addressable US market. CPH grows, increases revenue, SP goes up, you make money. Out with the traders, in with the investors please.